Adding a PARP inhibitor to standard therapy for metastatic pancreatic cancer can achieve substantially better outcomes for a small subgroup of patients with BRCA germline mutations, according to results presented at ASCO 2019. Data from the POLO trial suggest that olaparib maintenance treatment after platinum-based chemotherapy should be the new standard of care for patients ...
Olaparib delays metastatic pancreatic cancer progression in BRCA carriers
By Michael Woodhead
3 Jun 2019